Fig 1: Vaccinia virus equipped with both IL-12 and dnTGFβmm demonstrates superior antitumor activity and inclusion of CXCR3 enables systemic delivery by intravenous treatment. (A) Tumor growth inhibition by volume was assessed between groups of Renca tumor-bearing mice treated by intratumoral injection with either vehicle buffer or the indicated recombinant vaccinia virus (each n=20): left: vaccinia with inactivated TK gene; middle: vaccinia virus with IL-12, right: vaccinia virus with both IL-12 and TGF-β inhibitor transgenes; CR (where tumor volume shrank to <100 mm³) count/total group count. (B) Tumor volume was monitored over time after intravenous treatment of BALB/c mice bearing EMT-6 tumors with either 1×10⁷ PFU of TK⁻/A52⁻ control virus or indicated escalating doses of VET3-TGI-murine, versus vehicle control (n=10/group). (C) Same as B, but with C57BL/6 mice bearing MC-38 tumors. Groupwise comparisons were performed on median survivals from corresponding Kaplan-Meier analyses; ns, p>0.05, *p≤0.05, **p≤0.01, ****p≤0.0001; Mantel-Cox test with Holm-Šídák’s post hoc correction for multiple comparisons. (D), (E), (F) Kaplan-Meier survival analyses of subjects from A, B, and C, respectively, which were used to calculate and compare the effect of treatment on median survival times. (G) Postmortem count of lung metastases in an NNK-induced cancer model is displayed as box plot; *p≤0.05, one-way ANOVA on counts (vehicle n=15; dual-deletion virus n=14; VET3-TGI-surrogate n=7), with treatments compared with vehicle using Dunnett’s post hoc test. ANOVA, analysis of variance; CR, complete response; CXCR3, C-X-C motif chemokine receptor 3; IL-12, interleukin-12; NNK, N-nitrosamine ketone; ns, not significant; PFU, plaque-forming units; TGF-β, transforming growth factor beta; TK, thymidine kinase.
Supplier Page from Novus Biologicals, a Bio-Techne Brand for Recombinant Human CXCR3 GST (N-Term) Protein
Available conjugates: Sizes Available: 2 ug